LEERINK
CENTER FOR PHARMACOECONOMICS

READ THE REPORT

# Atherosclerotic Cardiovascular Disease

We compared the health-adjusted life expectancy, caregiving needs, medical costs, and workforce participation between an average person living with atherosclerotic cardiovascular disease (ASCVD) and a comparable person from the US general population. The differences between the two represent the unmet need and define the opportunity for innovation for the secondary prevention of ASCVD.

## PATIENT OPPORTUNITY

### Increase health-adjusted life expectancy

**3.0** discounted health-adjusted life years to recover

**$1.2-$4M**
value from improved health per person

## CAREGIVER OPPORTUNITY

### Free up time spent providing care

**150** hours of disease-related caregiving time to free up

**$2.4K**
ASCVD caregiving time to free up

## HEALTH SYSTEM OPPORTUNITY

### Reduce disease-related medical costs

**$67K** net medical cost savings after accounting for added costs of living longer

**$175K**
disease-related medical costs to avoid

## ECONOMIC OPPORTUNITY

### Restore workforce productivity

**0.3** full-time-equivalent years of productivity to recover

**$34K**
additional paid labor production

## ANALYTIC APPROACH AND CONTEXT

The report is about the broader progress that innovation in ASCVD could provide, not about the reimbursement or pricing of specific therapeutics. The analysis compares estimated outcomes for an average person living with ASCVD with an LDL cholesterol level of at least 70 mg/dL while receiving standard of care (i.e., moderate to high-intensity statin therapy with or without ezetimibe) to a comparable person in the general US population. Gaps in health-adjusted life expectancy, caregiving, medical costs, and workforce participation were monetized and discounted at a 3% discount rate. All monetary estimates are in 2025 US dollars. Importantly, societal value estimates by stakeholder group may not be additive, this not a comprehensive assessment of all societal impacts of ASCVD, and the interpretation of caregiver time findings are subject to important data limitations. Read the full report for more information.

LEERINK
CENTER FOR PHARMACOECONOMICS

AUTHOR:
**Melanie D. Whittington,** PhD, MS
Managing Director and Head
Leerink Center for Pharmacoeconomics

## Disclosures

The Center for Pharmacoeconomics ("CPE") is a division of MEDACorp LLC ("MEDACorp"). CPE is committed to advancing the understanding and evaluating the economic and societal benefits of healthcare treatments in the United States. Through its thought leadership, evaluations, and advisory services, CPE supports decisions intended to improve societal outcomes. MEDACorp, an affiliate of Leerink Partners LLC ("Leerink Partners"), maintains a global network of independent healthcare professionals providing industry and market insights to Leerink Partners and its clients. The information provided by the Center for Pharmacoeconomics is intended for the sole use of the recipient, is for informational purposes only, and does not constitute investment or other advice or a recommendation or offer to buy or sell any security, product, or service. The information has been obtained from sources that we believe reliable, but we do not represent that it is accurate or complete and it should not be relied upon as such. All information is subject to change without notice, and any opinions and information contained herein are as of the date of this material, and MEDACorp does not undertake any obligation to update them. This document may not be reproduced, edited, or circulated without the express written consent of MEDACorp.